Response to luspatercept can be predicted and improves overall survival in the real-life treatment of LR-MDS.

• Tác giả: Luis Aguirre, Najla H Al Ali, Cristina Amato, Gloria Andreossi, Alessia Campagna, Onyee Chan, Angela Consagra, Sven De Pourcq, Matteo G Della Porta, Bruno Fattizzo, Rami S Komrokji, Andrew Kuykendall, Jeffrey Lancet, Luca Lanino, Giulia Maggioni, Giorgio Mattiuz, Eric Padron, Alessandra Perego, Marco G Raddi, Francesco Restuccia, Luca Rigodanza, Marta Riva, David A Sallman, Alessandro Sanna, Valeria Santini, Michele Tanturli, Elena Tofacchi, Marta Ubezio, Alison Walker, Zhuoer Xie
• Ngôn ngữ: eng
• Thông tin xuất bản: United States : HemaSphere , 2025
• Bộ sưu tập: NCBI
• ID: 179206

Tóm tắt

 We explored the impact of luspatercept therapy on overall survival (OS) and possible predictors of response in low-risk (LR) myelodysplastic syndrome (MDS) patients. We evaluated 331 anemic patients treated with luspatercept. Hematological response (HI) was defined as (i) hemoglobin (Hb) increase of ≥1.5 g/dL in nontransfusion-dependent (NTD) patients, and (ii) red blood cell (RBC) transfusion independence (TI) with a concomitant Hb increase of ≥1.5 g/dL, or RBC-TI without an Hb increase of 1.5 g/dL, or >
 50% reduction in RBC transfusion burden (TB) for TD patients. Response was observed in 166 patients (50.2%), with significantly higher response in NTD and low TB versus high TB patients (